Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.35 |
| ▸ | TYMP | P19971 | 1/20 | 0.35 |
| ▸ | TK1 | P04183 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | LPO | P22079 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19888683 | 0.78 | TDP1 (0.37) | KMT2AMEN1ALDH1A1HPGDMAPT | |
| SCHEMBL16248 | 0.77 | MAPK1 (0.47) | ALDH1A1HPGDMAPK1TYMPTK1 | |
| SCHEMBL18069601 | 0.77 | ALDH1A1 (0.34) | KMT2AMEN1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL16575964 | 0.77 | LMNA (0.37) | KMT2AMEN1ALDH1A1HPGDMAPT | |
| SCHEMBL28313542 | 0.77 | KMT2A (0.35) | KMT2AMEN1ALDH1A1HPGDMAPT | |
| SCHEMBL23482940 | 0.77 | MAPK1 (0.36) | KMT2AMEN1ALDH1A1HPGDMAPT | |
| SCHEMBL28021080 | 0.77 | TK1 (0.36) | KMT2AMEN1ALDH1A1HPGDMAPT | |
| SCHEMBL28216800 | 0.77 | MAPK1 (0.40) | KMT2AMEN1ALDH1A1HPGDMAPT | |
| SCHEMBL6420314 | 0.76 | MAPK1 (0.46) | ALDH1A1HPGDMAPK1TYMPTK1 | |
| SCHEMBL24205178 | 0.74 | MAPK1 (0.45) | ALDH1A1HPGDMAPK1TYMPTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9875904-B2 | Silicon etching liquid, silicon etching method, and microelectromechanical element | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2018-01-23 | — | — | US | claimed |
| US-20150340241-A1 | SILICON ETCHING LIQUID, SILICON ETCHING METHOD, AND MICROELECTROMECHANICAL ELEMENT | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2015-11-26 | — | — | US | claimed |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | VERA THERAPEUTICS INC (US) | 2021-07-08 | — | — | US | disclosed |
| US-9875904-B2 | Silicon etching liquid, silicon etching method, and microelectromechanical element | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2018-01-23 | — | — | US | disclosed |
| US-20170369872-A1 | REVERSIR TM COMPOUNDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-9732110-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9675632-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150340241-A1 | SILICON ETCHING LIQUID, SILICON ETCHING METHOD, AND MICROELECTROMECHANICAL ELEMENT | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2015-11-26 | — | — | US | disclosed |
| US-8163707-B2 | 4′-allene-substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110257244-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110166198-A1 | RNA COMPOSITIONS FOR MODULATING IMMUNE RESPONSE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110065774-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | ALNYLAM PHARMACEUTICALS (US) | 2011-03-17 | — | — | US | disclosed |
| US-7851155-B2 | Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation | BOSTON PROBES, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7745126-B2 | Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation | BOSTON PROBES, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100074889-A1 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | disclosed |
| US-7638279-B2 | Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation | BOSTON PROBES, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090163381-A1 | Methods, Kits and Compositions Pertaining to Combination Oligomers and Libraries for Their Preparation | APPLERA CORPORATION. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080269074-A1 | Methods, Kits and Compositions Pertaining to Combination Oligomers and Libraries for Their Preparation | APPLERA CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080206747-A1 | Methods, Kits and Compositions Pertaining to Combination Oligomers and Libraries for Their Preparation | APPLERA COPORATION (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080085837-A1 | Methods, Kits and Compositions Pertaining to Combination Oligomers and Libraries for Their Preparation | APPLERA CORPORATION (US) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257244-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | AGO2, BCDIN3D, TRDMT1 | KMT2A 847/4885MEN1 1178/4885ALDH1A1 2937/4885 |
| US-20110065774-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | DCLRE1B, RNGTT, NSUN2 | KMT2A 943/4885MEN1 3523/4885ALDH1A1 1270/4885 |
| US-20100074889-A1 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | CCNI, CCNA1, CDK1 | KMT2A 3869/4885MEN1 4441/4885ALDH1A1 770/4885 |
| US-20110166198-A1 | RNA COMPOSITIONS FOR MODULATING IMMUNE RESPONSE | EIF2AK2, IRF3, NSUN2 | KMT2A 1526/4885MEN1 3843/4885ALDH1A1 4606/4885 |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | AGO2, TARBP1, TPR | KMT2A 1921/4885MEN1 2159/4885ALDH1A1 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.